Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 8—August 2013
Research

Duration of Immunity to Norovirus Gastroenteritis

Kirsten Simmons, Manoj Gambhir, Juan Leon, and Ben LopmanComments to Author 
Author affiliations: Rollins School of Public Health, Emory University, Atlanta, Georgia, USA (K. Simmons, J. Leon, B. Lopman); Centers for Disease Control and Prevention, Atlanta (K. Simmons, B. Lopman); Imperial College London, London, UK (M. Gambhir)

Main Article

Table 3

Duration of immunity, fitted parameter estimates, and log-likelihood and basic reproductive number for models of duration of immunity to norovirus gastroenteritis

Parameter Symbol Model A Model B Model C Model D Model E Model F
Duration of immunity, y θ 5.1 (3.9–6.5) 5.1 (4.0– 6.7) 8.7 (6.8–11.3) 4.1 (3.2–5.1) 7.6 (5.6–8.0) 5.1 (3.9–6.6)
Probability of transmission per infected contact, 0–4 y q1 0.25 (0.21–0.31) 0.18 (0.15–0.21) 0.37 (0.14–0.91) 0.35 (0.27–0.44) 0.23 (0.19–0.25) 0.25 (0.21–0.31)
Probability of transmission per infected contact, >5 y
q2
 0.050 (0.042–0.055)
 0.036 (0.032–0.039)
 0.094 (0.078–0.114))
 0.062 (0.057–0.066)
 0.051 (0.47–0.056)
 0.050 (0.046–0.054)
Negative log likelihood 615.497 613.905 663.052 616.597 611.509 615.375
Annual incidence, %† 5.2 5.3 5.5 5.1 3.8 5.2
Basic reproductive number (all ages) R0 1.79 1.64 3.34 1.88 1.73 1.79
Basic reproductive number (0–4 y) R0 4.33 3.98 6.41 4.84 3.98 4.33

*Model A, only symptomatic infectiousness; model B, presyymptomatic and postsymptomatic infectiousness (low); model C, presymptomatic and postsymptomatic infectiousness (high); model D, innate genetic resistance; model E, genogroup 2 type 4 (GII.4); model F, no immune boosting by asymptomatic infection.
†Compared with an observed annual incidence 4.5% from Phillips et al. (5), except for model E, which should be compared with norovirus GII.4-specific incidence of 3.2%.

Main Article

References
  1. Scallan  E, Griffin  PM, Angulo  FJ, Tauxe  RV, Hoekstra  RM. Foodborne illness acquired in the United States—unspecified agents. Emerg Infect Dis. 2011;17:16–22. DOIPubMedGoogle Scholar
  2. Hall  AJ, Rosenthal  M, Gregoricus  N, Greene  SA, Ferguson  J, Henao  OL, Incidence of acute gastroenteritis and role of norovirus, Georgia, USA, 2004–2005. Emerg Infect Dis. 2011;17:1381–8 .PubMedGoogle Scholar
  3. Lopman  B, Gastañaduy  P, Park  GW, Hall  AJ, Parashar  UD, Vinjé  J. Environmental transmission of norovirus gastroenteritis. Curr Opin Virol. 2012;2:96–102.
  4. Hall  AJ, Curns  AT, McDonald  LC, Parashar  UD, Lopman  BA. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999–2007. Clin Infect Dis. 2012;55:216–23. DOIPubMedGoogle Scholar
  5. Phillips  G, Tam  CC, Conti  S, Rodrigues  LC, Brown  D, Iturriza-Gomara  M, Community incidence of norovirus-associated infectious intestinal disease in England: improved estimates using viral load for norovirus diagnosis. Am J Epidemiol. 2010;171:1014–22. DOIPubMedGoogle Scholar
  6. Parker  SP, Cubitt  WD, Jiang  XJ, Estes  MK. Seroprevalence studies using a recombinant Norwalk virus protein enzyme immunoassay. J Med Virol. 1994;42:146–50 . DOIPubMedGoogle Scholar
  7. Jing  Y, Qian  Y, Huo  Y, Wang  LP, Jiang  X. Seroprevalence against Norwalk-like human caliciviruses in Beijing, China. J Med Virol. 2000;60:97–101. DOIPubMedGoogle Scholar
  8. Parrino  TA, Schreiber  D, Trier  J, Kapikian  A, Blacklow  N. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N Engl J Med. 1977;297:86–9. DOIPubMedGoogle Scholar
  9. Johnson  PC, Mathewson  JJ, DuPont  HL, Greenberg  HB. Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis. 1990;161:18–21, ONUDL 2153184.DOIPubMedGoogle Scholar
  10. Dolin  R, Blacklow  NR, DuPont  H, Formal  S, Buscho  RF, Kasel  J. Transmission of acute infectious nonbacterial gastroenteritis to volunteers by oral administration of stool filtrates. J Infect Dis. 1971;123:307–12. DOIPubMedGoogle Scholar
  11. Wyatt  RG, Dolin  R, Blacklow  NR, DuPont  HL, Buscho  RF, Thornhill  TS, Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis. 1974;129:709–14. DOIPubMedGoogle Scholar
  12. Graham  DY, Jiang  X, Tanaka  T, Opekun  AR, Madore  HP, Estes  MK. Norwalk virus infection of volunteers: new insights based on improved assays. J Infect Dis. 1994;170:34–43. DOIPubMedGoogle Scholar
  13. Reeck  A, Kavanagh  O, Estes  MK, Opekun  AR, Gilger  MA, Graham  DY, Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis. 2010;202:1212–8. DOIPubMedGoogle Scholar
  14. Atmar  RL, Bernstein  DI, Harro  CD, Al-Ibrahim  MS, Chen  WH, Ferreira  J, Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med. 2011;365:2178–87 . DOIPubMedGoogle Scholar
  15. Le Pendu  J, Ruvo  N, Kindberg  E, Svensson  L. Mendelian resistance to human norovirus infections. Semin Immunol. 2006;18:375–86. DOIPubMedGoogle Scholar
  16. Teunis  PFM, Moe  CL, Liu  P, Miller  SE, Lindesmith  L, Baric  RS, Norwalk virus: how infectious is it? J Med Virol. 2008;80:1468–76. DOIPubMedGoogle Scholar
  17. Johnson  PC, Mathewson  JJ, Dupont  HL, Greenberg  HB. Study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis. 1990;161:18–21. DOIPubMedGoogle Scholar
  18. Lindesmith  L, Moe  C, Marionneau  S, Ruvoen  N, Jiang  X, Lindblad  L, Human susceptibility and resistance to Norwalk virus infection. Nat Med. 2003;9:548–53. DOIPubMedGoogle Scholar
  19. Lindesmith  L, Moe  C, Lependu  J, Frelinger  JA, Treanor  J, Baric  RS. Cellular and humoral immunity following Snow Mountain virus challenge. J Virol. 2005;79:2900–9. DOIPubMedGoogle Scholar
  20. Atmar  RL, Opekun  AR. Gilger MA, Estes MK, Crawford SE, Neill FH, et al. Norwalk virus shedding after experimental human infection. Emerg Infect Dis. 2008;14:1553–7.
  21. Leon  JS, Kingsley  DH, Montes  JS, Richards  GP, Lyon  GM, Abdulhafid  GM, Randomized, double-blinded clinical trial for human norovirus inactivation in oysters by high hydrostatic pressure processing. Appl Environ Microbiol. 2011;77:5476–82. DOIPubMedGoogle Scholar
  22. Seitz  SR, Leon  JS, Schwab  KJ, Lyon  GM, Dowd  M, McDaniels  M, Norovirus infectivity in humans and persistence in water. Appl Environ Microbiol. 2011;77:6884–8. DOIPubMedGoogle Scholar
  23. Frenck  R, Bernstein  DI, Xia  M, Huang  P, Zhong  W, Parker  S, Predicting susceptibility to norovirus GII. 4 by use of a challenge model involving humans. J Infect Dis. 2012;206:1386–93. DOIPubMedGoogle Scholar
  24. Centers for Disease Control and Prevention. FastStats–Life expectancy [cited 2012 Sep 13]. http://www.cdc.gov/nchs/fastats/lifexpec.htm
  25. Rockx  B, De Wit  M, Vennema  H, Vinjé  J, De Bruin  E, Van Duynhoven  Y, Natural history of human calicivirus infection: a prospective cohort study. Clin Infect Dis. 2002;35:246–53. DOIPubMedGoogle Scholar
  26. Sukhrie  FHA, Siebenga  JJ, Beersma  MFC, Koopmans  M. Chronic shedders as reservoir for nosocomial transmission of norovirus. J Clin Microbiol. 2010;48:4303–5. DOIPubMedGoogle Scholar
  27. Rosenthal  NA, Lee  LE, Vermeulen  BAJ, Hedberg  K, Keene  WE, Widdowson  M-A, Epidemiological and genetic characteristics of norovirus outbreaks in long-term care facilities, 2003–2006. Epidemiol Infect. 2011;139:286–94. DOIPubMedGoogle Scholar
  28. Ozawa  K, Oka  T, Takeda  N, Hansman  GS. Norovirus infections in symptomatic and asymptomatic food-handlers in Japan. J Clin Microbiol. 2007;45:3996–4005. DOIPubMedGoogle Scholar
  29. Sukhrie  FHA, Teunis  P, Vennema  H, Copra  C, Beersma  MFCT, Bogerman  J, Nosocomial transmission of norovirus is mainly caused by symptomatic cases. Clin Infect Dis. 2012;54:931–7. DOIPubMedGoogle Scholar
  30. de Wit  MAS, Koopmans  MP, Kortbeek  LM, Wannet  WJ, Vinjé  J, Van Leusden  F, Sensor, a population-based cohort study on gastroenteritis in the Netherlands: incidence and etiology. Am J Epidemiol. 2001;154:666–74. DOIPubMedGoogle Scholar
  31. Mossong  J, Hens  N, Jit  M, Beutels  P, Auranen  K, Mikolajczyk  R, Social contacts and mixing patterns relevant to the spread of infectious diseases [cited 2012 Jul 13]. PLoS Med. 2008;5:e74. DOIPubMedGoogle Scholar
  32. Vega  E, Barclay  L, Gregoricus  N, Williams  K, Lee  D, Novel surveillance network for norovirus gastroenteritis. Emerg Infect Dis. 2011;17:1389–95 .PubMedGoogle Scholar
  33. Siebenga  JJ, Vennema  H, Zheng  D-P, Vinjé  J, Lee  BE, Pang  X-L, Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001–2007. J Infect Dis. 2009;200:802–12. DOIPubMedGoogle Scholar
  34. White  LJ, Mandl  JN, Gomes  MGM, Bodley-Tickell  AT, Cane  PA, Perez-Brena  P, Understanding the transmission dynamics of respiratory syncytial virus using multiple time series and nested models. Math Biosci. 2007;209:222–39. DOIPubMedGoogle Scholar
  35. Yen  C, Wikswo  ME, Lopman  BA, Vinje  J, Parashar  UD, Hall  AJ. Impact of an emergent norovirus variant in 2009 on norovirus outbreak activity in the United States. Clin Infect Dis. 2011;53:568–71. DOIPubMedGoogle Scholar
  36. Thomas-Crusells  J, McElhaney  JE, Aguado  MT. Report of the ad-hoc consultation on aging and immunization for a future WHO research agenda on life-course immunization. Vaccine. 2012;30:6007–12. DOIPubMedGoogle Scholar
  37. National Institutes of Health. ClinicalTrials.gov. Bivalent norovirus vaccine study [cited 2012 Sep 11]. http://clinicaltrials.gov/ct2/show/NCT01168401?term=norovirus+ligocyte&rank=2
  38. Zaman  K, Roy  E, Arifeen  SE, Rahman  M, Raqib  R, Wilson  E, Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med. 2008;359:1555–64. DOIPubMedGoogle Scholar
  39. Tamma  PD, Ault  KA, Rio  C, Steinhoff  MC, Halsey  NA, Omer  SB. Reviews Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol. 2009;201:547–52. DOIPubMedGoogle Scholar
  40. Steinhoff  MC, Omer  SB. Influenza immunization in pregnancy : antibody responses in mothers and infants. N Engl J Med. 2010;362:1644–6 . DOIPubMedGoogle Scholar
  41. Bartsch  SM, Lopman  BA, Hall  AJ, Parashar  UD, Lee  BY. The potential economic value of a human norovirus vaccine for the United States. Vaccine. 2012;30:7097–104. DOIPubMedGoogle Scholar

Main Article

Page created: July 19, 2013
Page updated: July 19, 2013
Page reviewed: July 19, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external